Idecabtagene vicleucel approved in US for multiple myeloma
This CAR-T therapy has been approved for use in adult relapsed or refractory multiple myeloma, after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody.
Source:
PharmaTimes